- Home
- CAI vs QGEN Comparison
CAI vs QGEN Comparison
Compare CAI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAI | QGEN |
|---|---|---|
| Founded | 2008 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.0B |
| IPO Year | 2025 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CAI | QGEN |
|---|---|---|
| Price | $32.13 | $50.37 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 12 |
| Target Price | $32.08 | ★ $49.20 |
| AVG Volume (30 Days) | 3.4M | ★ 4.6M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 5.48% |
| EPS Growth | ★ 69.79 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $812,033,000.00 | N/A |
| Revenue This Year | $26.78 | $2.20 |
| Revenue Next Year | $19.27 | $5.00 |
| P/E Ratio | ★ N/A | $24.01 |
| Revenue Growth | ★ 96.97 | N/A |
| 52 Week Low | $14.19 | $32.53 |
| 52 Week High | $32.89 | $57.82 |
Technical Indicators
Market Signals| Indicator | CAI | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 73.47 |
| Support Level | $16.52 | $49.37 |
| Resistance Level | $32.73 | $52.20 |
| Average True Range (ATR) | 1.80 | 1.21 |
| MACD | 0.07 | 0.50 |
| Stochastic Oscillator | 92.15 | 93.24 |
Price Performance
Historical ComparisonAbout CAI Caris Life Sciences Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).